Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: A prospective cohort study

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  López Cortés, Luis E ^a   Gálvez Acebal, Juan ^a,b,c   Del Toro, María D ^a,b,c   Velasco, Carmen ^b,c   De Cueto, Marina ^a,b   Caballero, Francisco J ^b   Muniain, Miguel A ^a,b,c   Pascual, Álvaro ^a,b,c   Rodríguez Baño, Jesús ^a,b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; TERTIARY HEALTHCARE; TREATMENT OUTCOME;

EID: 84893444616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082958     Document Type: Article

References (44)

1. Koh KK (2000) Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648-57.
2. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, et al. (1998) Direct vascular effects of HMGCoA reductase inhibitors. Atherosclerosis 137:S101-9. (Pubitemid 28294215)
3. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM (2009) Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 29:621-30.
4. su J, Andes DR, Knasinski V, Pirsch J, Safdar N (2009) Statins are associated with improved outcomes of bloodstream infection in solid-organ transplant recipients. Eur J Clin Microbiol Infect Dis 28:1343-51.
5. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32: 75-9. (Pubitemid 43039379)
6. Martin CP, Talbert RL, Burgess DS, Peters JI (2007) Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27:20-6. (Pubitemid 46067959)
7. Fernández R, De Pedro VJ, Artigas A (2006) Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 32:160-4. (Pubitemid 43039392)
8. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sørensen HT, et al. (2006) Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 34:1080-6.
9. ang KC, Chien JY, Tseng WK, Hsueh PR, Yu CJ, et al. (2007) Statins do not improve short term survival in an oriental population with sepsis. Am J Emerg Med 25:494-501.
10. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J (2010) The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 25: 656.e7-22.
11. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, et al. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-17. (Pubitemid 39050477)
12. Rodríguez-Baño J, López-Prieto MD, Portillo MM, Retamar P, Natera C, et al. (2010) Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect 16:1408-1413.
13. Retamar P, Portillo MM, López-Prieto MD, Rodríguez- López F, de Cueto M, et al. (2012) Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 56:472-8.
14. Horn MP, Knecht SM, Rushing FL, Birdsong J, Siddall CP, et al. (2008) Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther 326: 135-143, (Pubitemid 351872123)
15. Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, et al. (2002) Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 106:2104-2110. (Pubitemid 35192817)
16. Rodríguez-Baño J, de Cueto M, Retamar P, Gálvez-Acebal J (2010) Current management of bloodstream infections. Expert Rev Anti Infect Ther 8: 815-29.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al STROBE-Initiative. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies. PLoS Med 4: e296.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383. (Pubitemid 17055592)
19. Lesens O, Methlin C, Hansmann Y, Remy V, Martinot M, et al. (2003) Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol 24:890-6. (Pubitemid 38029555)
20. Chang FY, MacDonald BB, Peacock JE Jr, Musher DM, Triplett P, et al. (2003) A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82:322-32. (Pubitemid 37229467)
21. Gasch O, Camoez M, Domínguez MA, Padilla B, Pintado V, et al. (2013) Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 68:1423-30.
22. Kim SH, Park WB, Lee KD, Kang CI, Kim HB, et al. (2003) Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus none-radicable foci. Clin Infect Dis 37:794-9.
23. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 20:864-74.
24. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, et al. (2008) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 36:296-327.
25. Rieg S, Peyerl-Hoffmann G, de With K, Theilacker C, Wagner D, et al. (2009) Mortality of S. aureus bacteremia and infectious diseases specialist consultation: a study of 521 patients in Germany. J Infect 59: 232-239.
26. Raad II, Sabbagh MF (1992) Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 14:75-82.
27. Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, et al. (1998) Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 27:478-86. (Pubitemid 28421994)
28. Lahey T, Shah R, Gittzus J, Schwartzman J, Kirkland K (2009) Infectious Diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine (Baltimore) 88, 263-267.
29. Tenover C, Moellering R (2007) The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208-1215.
30. McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, et al. (2007) A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 45:329-37. (Pubitemid 47101029)
31. Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352-7. (Pubitemid 32955186)
32. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, et al. (2009) Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 41:4-9.
33. Johnson JR (2008) Persistent Staphylococcus aureus bacteremia. Arch Intern Med 168:772-3.
34. Xiong YQ, Fowler VG, Yeaman MR, Perdreau-Remington F, Kreiswirth BN, et al. (2009) Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis 199:201-8.
35. Jenkins TC, Price CS, Sabel AL, Mehler PS, Burman WJ (2008) Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 46:1000-8. (Pubitemid 351589864)
36. Almog Y, Novack V, Eisinger M, Porath A, Novack L, et al. (2007) The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 35:372-8. (Pubitemid 46148524)
37. Gupta R, Plantinga LC, Fink NE, Melamed ML, Coresh J, et al. (2007) Statin use and sepsis events in patients with chronic kidney disease. JAMA 297:1455-64. (Pubitemid 46556471)
38. Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, et al. (2006) Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 38:7-14. (Pubitemid 43123837)
39. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ (2010) Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 65:1015-8.
40. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, et al. (2009) Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 41:4-9.
41. Fowler VG Jr, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, et al. (2004) Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 190:1140-1149. (Pubitemid 39186802)
42. Yeaman M (1997) The role of platelets in antimicrobial host defense. Clin Infect Dis 25:951-68.
43. Viasus D, Garcia-Vidal C, Gudiol F, Carratalá J (2010) Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis 29:143-152.
44. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 333:999.